IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled "Press Release Financial Results for the quarter and year ended 31st March 2026".
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IOL Chemicals reported its highest-ever quarterly revenue of ₹619.5 crore in Q4 FY26, up 17.4% year-on-year. Profitability surged significantly with EBITDA growing 39.8% to ₹94.3 crore and PAT jumping 68.2% to ₹53.2 crore, while margins expanded by over 250 basis points each. For the full year FY26, revenue stood at ₹2,319.1 crore with 11.5% growth, EBITDA at ₹290.4 crore with 29.3% growth, and PAT at ₹137.7 crore with 36.4% growth. The Pharmaceuticals segment drove growth through increased non-Ibuprofen products like Paracetamol and Metformin, while the Chemicals segment nearly doubled its EBIT year-on-year. The company incurred ₹164 crore capex for capacity expansion funded through internal accruals.
Strong operational performance with margin expansion signals improved execution and better product mix, which could positively influence investor sentiment and support the stock price given the robust profit growth and diversified revenue streams.